Table 1. Preoperative analysis of Fibrinogen, NLR, and PLR in thymic epithelial tumors.
| Characteristics | n | Fibrinogen | p-value | n | NLR | p-value | n | PLR | p-value |
|---|---|---|---|---|---|---|---|---|---|
| mean (median) ± SD (SEM) | mean (median) ± SD (SEM) | mean (median) ± SD (SEM) | |||||||
| TETs | 112 | 390.2 (360.5) ± 120.6 (11.4) | 102 | 3.43 (2.64) ± 2.59 (0.3) | 95 | 179.8 (142.4) ± 118.0 (12.1) | |||
| Controls | 27 | 314.8 (315.0) ± 56.5 (10.9) | <0.001a | 51 | 1.78 (1.63) ± 0.75 (0.1) | <0.001a | 48 | 133.4 (124.4) ± 49.4 (7.1) | 0.001a |
| Age (years) | |||||||||
| <57 | 54 | 375.0 (328.5) ± 121.3 (16.5) | 48 | 3.47 (2.49) ± 2.79 (0.40) | 44 | 184.7 (150.0) ± 107.2 (16.2) | |||
| ≥57 | 58 | 404.3 (370.5) ± 119.3 (15.7) | 0.201a | 54 | 3.40 (2.86) ± 2.42 (0.33) | 0.888a | 51 | 175.7 (142.0) ± 127.4 (17.8) | 0.715a |
| Sex | |||||||||
| Male | 46 | 397.6 (369.5) ± 139.5 (20.6) | 40 | 3.69 (2.92) ± 2.41 (0.38) | 37 | 180.3 (138.7) ± 99.2 (16.3) | |||
| Female | 66 | 384.9 (353.0) ± 106.3 (13.1) | 0.586a | 62 | 3.27 (2.53) ± 2.71 (0.34) | 0.419a | 58 | 179.5 (150.0) ± 129.3 (17.0) | 0.976a |
| WHO | |||||||||
| MNT | 7 | 331.7 (327.0) ± 90.8 (34.3) | 7 | 5.10 (2.42) ± 3.81 (1.44) | 7 | 252.6 (274.4) ± 142.3 (53.8) | |||
| A | 14 | 405.2 (385.5) ± 82.0 (21.9) | 14 | 3.32 (3.04) ± 2.04 (0.59) | 12 | 198.8 (167.8) ± 89.6 (25.9) | |||
| AB | 16 | 341.5 (315.5) ± 104.1 (26.0) | 16 | 2.93 (2.97) ± 0.82 (0.21) | 14 | 140.7 (126.3) ± 59.0 (15.8) | |||
| B1 | 10 | 361.9 (358.5) ± 54.8 (17.3) | 10 | 2.19 (0.18) ± 0.49 (0.15) | 10 | 110.7 (83.8) ± 47.3 (15.0) | |||
| B2 | 22 | 364.7 (351.5) ± 87.8 (18.7) | 22 | 2.70 (2.47) ± 1.89 (0.42) | 18 | 124.5 (108.6) ± 58.1 (13.7) | |||
| B3 | 15 | 363.5 (334.0) ± 96.9 (25.0) | 15 | 2.71 (2.53) ± 1.47 (0.39) | 13 | 152.4 (139.5) ± 71.3 (19.8) | |||
| TC | 28 | 469.4 (473.0) ± 163.4 (30.9) | 0.003b | 28 | 5.09 (4.05) ± 3.84 (0.82) | 0.005b | 21 | 268.2 (230.0) ± 169.6 (37.0) | <0.001b |
| Tumor Stage I | |||||||||
| I | 25 | 354.5 (346.0) ± 65.1 (13.0) | 25 | 2.84 (2.44) ± 1.69 (0.36) | 20 | 171.3 (163.6) ± 74.4 (16.7) | |||
| II | 53 | 364.1 (352.0) ± 96.9 (13.3) | 53 | 3.09 (2.69) ± 2.08 (0.29) | 48 | 145.3 (129.4) ± 79.3 (11.5) | |||
| III | 11 | 428.1 (415.0) ± 126.5 (38.1) | 11 | 4.74 (4.10) ± 3.88 (1.29) | 9 | 268.9 (281.4) ± 145.5 (48.5) | |||
| IV | 23 | 470.8 (465.0) ± 169.3 (35.3) | 0.001b | 23 | 4.45 (3.22) ± 3.54 (0.81) | 0.061b | 18 | 236.9 (173.0) ± 179.7 (42.4) | 0.003b |
| Tumor Stage II | |||||||||
| Early I-II | 78 | 361.0 (349.5) ± 87.7 (9.93) | 74 | 3.01 (2.61) ± 1.97 (0.23) | 68 | 152.9 (135.6) ± 78.3 (9.49) | |||
| Advanced III-IV | 34 | 457.0 (463.0) ± 156.1 (26.8) | 0.002b | 28 | 4.54 (3.31) ± 3.58 (0.68) | 0.040b | 27 | 247.6 (177.1) ± 166.9 (32.1) | 0.008b |
| Myasthenia Gravis | |||||||||
| Yes | 31 | 351.8 (330.0) ± 102.3 (18.4) | 31 | 3.11 (2.40) ± 2.75 (0.53) | 26 | 161.5 (133.5) ± 148.4 (29.1) | |||
| No | 81 | 404.8 (368.0) ± 124.5 (13.8) | 0.037a | 81 | 3.55 (2.83) ± 2.54 (0.29) | 0.455a | 69 | 186.7 (158.8) ± 104.7 (12.6) | 0.356a |
Preoperative Fibrinogen serum values, NLR and PLR are shown with regards to sex, age, WHO classification, tumor stage and Myasthenia Gravis. Data are indicates as mean (median) ± SD (SEM). NLR, Neutrophil-to-Lymphocyte Ratio; PLR, Platelet-to-Lymphocyte Ratio; SD, standard deviation; SEM, standard error of the mean; TETs, Thymic Epithelial Tumors; WHO, World Health Organization classification of histologic tumor subtype. aunpaired Student’s t-test; b one-way ANOVA.